Drugs / AZD8421
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06188520 | Dec 2023 → Aug 2027 expected | estrogen-receptor positive breast cancer, ovarian serous adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8421 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06188520 ↗ |
| Action | Inhibit | “CDK2 inhibitor” NCT06188520 ↗ |
| Target | CDK2 | “CDK2 inhibitor” NCT06188520 ↗ |